Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants

Muhammed Olanrewaju Afolabi, Alfred B. Tiono, Uche J. Adetifa, Jean Baptiste Yaro, Abdoulie Drammeh, Issa Nébié, Carly M Bliss, Susanne H Hodgson, Nicholas A Anagnostou, Guillaume S. Sanou, Ya Jankey Jagne, Oumarou Ouedraogo, Casimir Tamara, Nicolas Ouedraogo, Mirielle Ouedraogo, Jainaba Njie-jobe, Amidou Diarra, Christopher J A Duncan, Riccardo Cortese, Alfredo L NicosiaRachel Roberts, Nicola K Viebig, Odile Leroy, Alison M Lawrie, Katie L. Flanagan, Beate Kampman, Philip A Bejon, Egeruan Babatunde Imoukhuede, Katie J Ewer, Adrian V S Hill, Kalifa Abubakr Bojang, Sodiomon B. Sirima

Research output: Contribution to journalArticleResearchpeer-review

25 Citations (Scopus)


Malaria remains a significant global health burden and a vaccine would make a substantial contribution to malaria control. Chimpanzee Adenovirus 63 Modified Vaccinia Ankara Multiple epitope thrombospondin adhesion protein (ME-TRAP) and vaccination has shown significant efficacy against malaria sporozoite challenge in malaria-naive European volunteers and against malaria infection in Kenyan adults. Infants are the target age group for malaria vaccination; however, no studies have yet assessed T-cell responses in children and infants. We enrolled 138 Gambian and Burkinabe children in four different age-groups: 2-6 years old in The Gambia; 5-17 months old in Burkina Faso; 5-12 months old, and also 10 weeks old, in The Gambia; and evaluated the safety and immunogenicity of Chimpanzee Adenovirus 63 Modified Vaccinia Ankara ME-TRAP heterologous prime-boost immunization. The vaccines were well tolerated in all age groups with no vaccine-related serious adverse events. T-cell responses to vaccination peaked 7 days after boosting with Modified Vaccinia Ankara, with T-cell responses highest in 10 week-old infants. Heterologous prime-boost immunization with Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara ME-TRAP was well tolerated in infants and children, inducing strong T-cell responses. We identify an approach that induces potent T-cell responses in infants, which may be useful for preventing other infectious diseases requiring cellular immunity.

Original languageEnglish
Pages (from-to)1470-1477
Number of pages8
JournalMolecular Therapy
Issue number8
Publication statusPublished - 1 Aug 2016

Cite this